Meeting
2017 ASCO Annual Meeting
Typical bronchial NETs as a misleading biology.
Authors
Dalvinder Mandair
Royal Free Hospital Neuroendocrine Tumour Unit, London, United Kingdom
Dalvinder Mandair , Leonidas-Nikolaos Diamantopoulos , George Demetriou , Faidon Laskaratos , Christos Toumpanakis , Martyn E. Caplin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 35, 2017 (suppl; abstr 8528)
DOI
10.1200/JCO.2017.35.15_suppl.8528
Abstract #
8528
Poster Bd #
264
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Cost-effectiveness of a circulating tumor fraction molecular biomarker for treatment response monitoring.
First Author: Zachary Rivers
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Assessment of hematological toxicity in patients with advanced neuroendocrine tumors and extensive/innumerable bone metastases undergoing lutetium-177 DOTATATE treatment.
First Author: Osama M Mosalem
Poster
2022 ASCO Annual Meeting
Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.
First Author: Jennifer Rachel Eads
Poster
2020 ASCO Virtual Scientific Program
Safety of 177Lu‑DOTATATE in patients with advanced neuroendocrine tumors: Data from a U.S. expanded access program.
First Author: Martin S. Auerbach